B Group Inc’s Apogee Therapeutics APGE Stock Holding History

B Group Inc’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-7,500	Closed	-$631K	–	20
2026 Q1	$631K	Sell	7,500 -12,500	-63%	-$908K	0.47%	17
2025 Q4	$1.51M	Sell	20,000 -15,000	-43%	-$945K	1.11%	15
2025 Q3	$1.39M	Hold	35,000	–	–	1.02%	17
2025 Q2	$1.52M	Buy	35,000 +5,000	+17%	+$190K	1.17%	14
2025 Q1	$1.12M	Buy	30,000 +15,000	+100%	+$580K	0.96%	15
2024 Q4	$680K	Buy	+15,000	New	+$765K	0.42%	14

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

B Group Inc's APGE Position: Q2 2026 in Review

B Group Inc sold out of Apogee Therapeutics (APGE) in Q2 2026, closing a stake of 7,500 shares — an estimated $631K sold.

B Group Inc first reported a position in APGE in Q4 2024 and held it in 6 quarters. The position peaked at $1.52M in Q2 2025. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

B Group Inc reported no remaining Apogee Therapeutics position as of Q2 2026 after selling out during the quarter.
B Group Inc sold 7,500 Apogee Therapeutics shares in Q2 2026, an estimated $631K.
B Group Inc first reported a position in Apogee Therapeutics in Q4 2024 and held it in 6 quarters.
B Group Inc's Apogee Therapeutics position peaked at $1.52M in Q2 2025.
289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on B Group Inc's 13F filing for Q2 2026, filed 14 Aug 2026.